{"schema_version":"secwatch.filing_event.v1","accession":"0001372514-24-000027","form_type":"8-K","ticker":"KPRX","cik":"0001372514","company_name":"KIORA PHARMACEUTICALS INC","filed_at":"2024-03-25T23:59:59+00:00","discovered_at":"2026-05-14T18:03:23.982866+00:00","generated_at":"2026-06-04T08:22:45.346878+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Kiora reports 2023 net loss $12.5M; cash >$30M post partnership and placement","bullets":["Net loss $12.5M in 2023 vs $13.6M in 2022; R&D expense $4.0M, G&A $4.7M.","Cash and equivalents $2.5M at year-end 2023; $16M upfront from TOI partnership and $13.8M private placement net proceeds in Feb 2024 raised cash >$30M.","Company expects existing cash to fund operations through 2026.","KIO-301 Phase 2 trial in retinitis pigmentosa expected to start Q4 2024; KIO-104 Phase 2 planning underway.","Partnership with Théa Open Innovation grants exclusive rights to KIO-301 outside Asia; potential milestones up to $285M plus tiered royalties."],"urls":{"canonical":"https://secwatch.observer/filing/0001372514-24-000027","json":"https://secwatch.observer/filing/0001372514-24-000027.json","markdown":"https://secwatch.observer/filing/0001372514-24-000027.md","text":"https://secwatch.observer/filing/0001372514-24-000027.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1372514/000137251424000027/0001372514-24-000027-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1372514/000137251424000027/kprx-20240325.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T08:22:45.346878+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"027419fe81d2723d33e17545750abfa8a34f7c68","claim":"KIORA PHARMACEUTICALS INC reported financial results for the year ended December 31, 2023.","evidence_excerpt":"Kiora Pharmaceuticals, Inc. (the \"Company\") issued a press release announcing financial results for the year ended December 31, 2023 and an update on clinical development progress.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1372514/000137251424000027/0001372514-24-000027-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the year ended December 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}